Foghorn Therapeutics (NASDAQ:FHTX – Get Free Report) will likely be posting its quarterly earnings results before the market opens on Thursday, March 6th. Analysts expect Foghorn Therapeutics to post earnings of ($0.43) per share and revenue of $8.56 million for the quarter.
Foghorn Therapeutics Trading Down 10.9 %
Shares of FHTX stock opened at $4.32 on Tuesday. Foghorn Therapeutics has a 12 month low of $3.86 and a 12 month high of $10.25. The company has a market capitalization of $240.24 million, a P/E ratio of -2.25 and a beta of 3.18. The stock has a 50 day moving average of $4.75 and a two-hundred day moving average of $6.78.
Analysts Set New Price Targets
Several brokerages recently commented on FHTX. Jefferies Financial Group reduced their target price on Foghorn Therapeutics from $18.00 to $14.00 and set a “buy” rating for the company in a research report on Monday, December 16th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 price objective (down from $20.00) on shares of Foghorn Therapeutics in a report on Tuesday, December 17th. Finally, B. Riley started coverage on shares of Foghorn Therapeutics in a research note on Thursday, January 30th. They issued a “buy” rating and a $10.00 target price on the stock. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $13.17.
Foghorn Therapeutics Company Profile
Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.
Further Reading
- Five stocks we like better than Foghorn Therapeutics
- Are Penny Stocks a Good Fit for Your Portfolio?
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Options Trading – Understanding Strike Price
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- How to start investing in penny stocks
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Foghorn Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foghorn Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.